Abstract 6822: Impact of Lipoprotein(a) Testing on Lipid-Lowering Therapy Use and LDL-C Goal Attainment in Patients with Atherosclerotic Cardiovascular Disease: A Difference-in-Differences Analysis
Background: Elevated lipoprotein(a) [Lp(a)] is an independent, genetically determined causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and can refine risk assessment and, in the absence of targeted therapies, inform lipid lowering therapy (LLT) decisions. Although clinical guidelines recommend m...